26 results
8-K
EX-99.1
IVVD
Invivyd Inc
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down of adintrevimab clinical trials
8-K
EX-99.1
IVVD
Invivyd Inc
9 Feb 24
Index to Consolidated Financial Statements
4:01pm
minimum purchase commitments. Certain of these agreements provide for termination rights subject to the payment of termination fees and/or wind-down
8-K
EX-99.1
IVVD
Invivyd Inc
9 Nov 23
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:10pm
trial costs in 2022 due to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down
8-K
EX-99.1
n8w8ixtk2
11 May 23
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm
8-K
EX-99.1
szzo eqso3e9
10 Nov 22
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
4:13pm
10-K
dnqhh bibur48t
31 Mar 22
Annual report
8:18am
10-Q
u9uwv7y8ibns 9fq46rp
20 Sep 21
Quarterly report
4:17pm
424B4
tgq11w6pdt0zu98 7q5t
6 Aug 21
Prospectus supplement with pricing info
4:54pm
S-1/A
rpu575rd4o
2 Aug 21
IPO registration (amended)
6:20am
S-1
EX-10.7
e999zlo1iy1z0zlk35pg
16 Jul 21
IPO registration
4:56pm